

# Sirtuin-6 Preserves R-spondin-1 Expression and Increases Resistance of Intestinal Epithelium to Injury in Mice

Fangyi Liu,<sup>1,2,3</sup> Heng-Fu Bu,<sup>2,3</sup> Hua Geng,<sup>2,3</sup> Isabelle G De Plaen,<sup>2,3</sup> Chao Gao,<sup>4</sup> Peng Wang,<sup>2,3</sup> Xiao Wang,<sup>2,3</sup> Jacob A Kurowski,<sup>2,3</sup> Hong Yang,<sup>1</sup> Jiaming Qian,<sup>1</sup> and Xiao-Di Tan<sup>2,3,5</sup>

<sup>1</sup>Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China; <sup>2</sup>Center for Intestinal and Liver Inflammation Research, Stanley Manne Children's Research Institute, Ann and Robert H Lurie Children's Hospital of Chicago, Chicago, Illinois, United States of America; <sup>3</sup>Department of Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States of America; <sup>4</sup>Center of Clinical Reproductive Medicine, State Key Laboratory of Reproductive Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, People's Republic of China; and <sup>5</sup>Department of Research and Development, Jesse Brown VA Medical Center, Chicago, Illinois, United States of America

Sirtuin-6 (Sirt6) is a critical epigenetic regulator, but its function in the gut is unknown. Here, we studied the role of intestinal epithelial Sirt6 in colitis-associated intestinal epithelial injury. We found that Sirt6, which is predominantly expressed in epithelial cells in intestinal crypts, is decreased in colitis in both mice and humans. Colitis-derived inflammatory mediators including interferon- $\gamma$  and reactive oxygen species strongly inhibited Sirt6 protein expression in young adult mouse colonocyte (YAMC) cells. The susceptibility of the cells to injurious insults was increased after knockdown of Sirt6 expression. In contrast, YAMC cells with Sirt6 overexpression exhibited more resistance to injurious insult. Furthermore, intestinal epithelial-specific Sirt6 (*Sirt6<sup>IEC-KO</sup>*) knockout mice exhibited greater susceptibility to dextran sulfate sodium (DSS)-induced colitis. RNA sequencing transcriptome analysis revealed that inflammatory mediators such as tumor necrosis factor (TNF)- $\alpha$  suppressed expression of R-spondin-1 (*Rspo1*, a critical growth factor for intestinal epithelial cells) in Sirt6-silenced YAMC cells *in vitro*. In addition, lipopolysaccharide was found to inhibit colonic *Rspo1* expression in *Sirt6<sup>IEC-KO</sup>* mice but not their control littermates. Furthermore, *Sirt6<sup>IEC-KO</sup>* mice with DSS-induced colitis also exhibited a significant decrease in *Rspo1* expression in colons. *In vitro*, knockdown of *Rspo1* attenuated the effect of ectopic expression of Sirt6 on protection of YAMC cells against cell death challenges. In conclusion, Sirt6 plays an important role in protecting intestinal epithelial cells against inflammatory injury in a mechanism associated with preserving *Rspo1* levels in the cells.

Online address: <http://www.molmed.org>

doi: 10.2119/molmed.2017.00085

## INTRODUCTION

Inflammatory bowel disease (IBD) is an idiopathic disorder affecting approximately 1.5 million Americans and others worldwide (1,2). The incidence of IBD seems to be increasing in many

regions of the world (2,3). Crypt epithelial cell damage associated with colonic inflammation is a distinctive pathological hallmark of IBD (4). However, prevention and treatment of IBD remain a challenge, as the pathogenesis of the

disease is unknown (5). Therefore, there is a strong rationale for exploring novel therapeutic targets that can be applied to strengthen epithelial cells against injurious insults for management of patients with IBD.

The sirtuins are a family of proteins that mainly function as nicotinamide adenine dinucleotide-dependent deacetylases (6). In mammals, there are seven sirtuin proteins, Sirt1 to Sirt7 (6). Among them, Sirt1 and Sirt6 are the most well-characterized, with functions associated with inflammation. Sirt1 is a cytosolic protein with nuclear translocation ability. Previous studies have shown that Sirt1 plays a role in regulation of inflammatory signals in the gut (7,8). In contrast, Sirt6 is a nuclear and chromatin-bound protein that emerges as an important epigenetic regulator

---

**Address correspondence to** Xiao-Di Tan, Stanley Manne Children's Research Institute Ann and Robert H Lurie Children's Hospital of Chicago, 225 E. Chicago Avenue, Box 217, Chicago, IL 60611, USA. Phone: (773) 755-6380; Fax: (773) 755-6581; E-mail: [xtan@northwestern.edu](mailto:xtan@northwestern.edu). Or to Jiaming Qian, Department of Gastroenterology, Peking Union Medical College Hospital, No. 1, Shualifuyuan, Dongcheng District, Beijing, 100730, People's Republic of China. Tel: (86) 10 69155019; E-mail: [qianjiaming1957@126.com](mailto:qianjiaming1957@126.com)  
Submitted May 17, 2017; Accepted for Publication August 28, 2017;  
Published Online ([www.molmed.org](http://www.molmed.org)) October 23, 2017.

controlling a number of metabolic and survival processes in cells (9). Recently, Kanfi *et al.* reported that mice overexpressing *Sirt6* have increased longevity (10). *Sirt6* knockout mice were found to die within one month after birth due to numerous abnormalities, including profound lymphopenia, loss of subcutaneous fat, lordokyphosis and severe metabolic defects (11). Evidence suggests that *Sirt6* has both proinflammatory and antiinflammatory roles, depending on the context and cell type involved (9). Currently, the exact role of *Sirt6* in intestinal epithelial cells remains unknown, and how it is affected during intestinal inflammation has not been explored.

In this study, our objectives were to evaluate the function of *Sirt6* in intestinal epithelial cells and to determine the link between *Sirt6* and colitis-associated intestinal epithelial injury using both *in vivo* and *in vitro* approaches. To this end, we first studied whether colitis development was associated with alterations in colonic *Sirt6* expression in mice and humans. Then, using mice with intestinal epithelial cells deficient in the *Sirt6* gene, we assessed the role of epithelial cell *Sirt6* in dextran sulfate sodium (DSS)-induced intestinal injury. Furthermore, we confirmed the direct role of *Sirt6* in intestinal epithelial cells *in vitro* in response to specific injurious insults using gain- and loss-of-function approaches. Finally, we explored downstream molecules mediating the protective effects of *Sirt6* on intestinal epithelial cell damage induced by inflammation using gene silencing and RNA sequencing (RNA-seq) technology. We found that *Sirt6* plays an important role in maintaining intestinal epithelial cell resistance to injurious insult via a mechanism involving R-spondin-1 (*Rspo1*) protein, a critical epithelial mitogen that stimulates intestinal crypt cell growth in inflammation. This study may open a new avenue for the development of therapeutic targets to maintain intestinal epithelial integrity in colitis in the future.

## MATERIALS AND METHODS

### Animals

C57BL/6J mice, *Villin-Cre* transgenic mice and *Sirt6* conditionally mutated (*Sirt6<sup>Co/Co</sup>*) mice were obtained from Jackson Laboratories (Bar Harbor, ME, USA). The *Villin-Cre* transgenic mice express Cre recombinase specifically in intestinal epithelium (12), whereas the *Sirt6<sup>Co/Co</sup>* mice possess *loxP* sites flanking exons 2–3 of the *Sirt6* gene, as previously described (13). Intestinal epithelium-specific *Sirt6* knockout mice (*Sirt6<sup>Co/Co</sup>*, *Villin-Cre* or *Sirt6<sup>IEC-KO</sup>* mice) were generated by intercrossing *Sirt6<sup>Co/Co</sup>* mice with *Villin-Cre* mice. Mouse genotypes were confirmed using polymerase chain reaction (PCR)-based protocols provided by Jackson Laboratories. Co-housed littermates carrying the *LoxP*-flanked alleles but not expressing Cre recombinase were used as controls for *Sirt6<sup>IEC-KO</sup>* mice. All mice were housed in a specific pathogen-free animal facility at the Stanley Manne Children's Research Institute. Animal husbandry was provided by trained technicians and veterinarians. All the animal experimental procedures were conducted in accordance with the National Institutes of Health guidelines and were approved by the Institutional Animal Care and Use Committee of Northwestern University.

### Induction of Colitis

Colitis was induced in mice using our previously published protocol (14). Briefly, mice (male, 8–10 wks old) fed a normal diet were given *ad libitum* access to 3.5% DSS (m.w. 36,000–50,000; MP Biomedicals, Solon, OH, USA) to drink for up to 1 wk. Control mice were given regular drinking water. During experiments, mice were weighed and stools were tested for occult blood on a daily basis. The disease activity index of clinical colitis was calculated using our well-established scoring system, as previously described (14). At the end of time points indicated, mice were euthanized by CO<sub>2</sub> inhalation. Colons and blood were collected. Blood was

processed for isolation of plasma by centrifugation at 1,000g for 10 min at 4°C. Plasma samples and colonic tissues were stored at –80°C until used. In some experiments, whole colon tissues were processed for histological analysis, as described below.

### Histology and Microscopic Examination

The fresh colonic tissues were fixed in 10% neutral buffered formalin and processed for routine histology as described before (15). Hematoxylin and eosin stained sections (5 μm) were examined under a light microscope using a scoring system in a blinded manner (14). Briefly, three independent parameter scores were measured: severity of inflammation (0 to 3: none, slight, moderate, severe); depth of injury (0 to 3: none, mucosal, mucosal and submucosal, transmural); and crypt damage (0 to 4: none, basal one-third damaged, basal two-thirds damaged, only surface epithelium intact, entire crypt and epithelium lost). Then, percent involvement of the colon tissues was estimated. Each parameter score was multiplied by the percentage of tissue involved and totals were added together to obtain a histopathology score.

### Immunofluorescent Staining

Deparaffinized slides were processed for immunofluorescent staining using a method modified from our previously published protocol (16). Specifically, deparaffinized slides were hydrated through series alcohol, incubated in 10 mM sodium citrate buffer (pH 6.0) at 95–100°C for 15 min for antigen retrieval, and gradually cooled to room temperature for 45 min. Then, slides were treated with 10% goat serum (Vector Labs, Burlingame, CA, USA) for 1 h at room temperature to block nonspecific binding sites in tissues. Thereafter, slides were stained with rabbit monoclonal antibody against *Sirt6* (1:50, CST, Danvers, MA, USA) at 4°C overnight. The negative control slides were stained with naïve rabbit IgG (R&D, Minneapolis,

MN, USA). After washing with phosphate buffered saline (PBS), slides were incubated with goat anti-rabbit IgG antibody labeled with Alexa Fluor 488 (1:250; Thermo Fisher Scientific, Waltham, MA, USA) for 90 min at 37°C in the dark. Finally, slides were washed with PBS and mounted using mounting solution containing DAPI (Vector Labs). Slides were examined under an upright fluorescence microscope (model MD R; Leica Microsystems) using appropriate filters. Images were acquired with a digital camera (QImaging Retiga 4000R), transferred to an Apple iMac computer, analyzed by Openlab image analysis software and assembled with Adobe Photoshop CS5 software.

### Human Samples

All studies were performed in accordance with protocols approved by the Human Research Ethics Committee at Peking Union Medical College Hospital, Beijing, China. In this study, we recruited 15 patients with ulcerative colitis (UC) who required diagnostic colonoscopy and 17 healthy individuals undergoing colonoscopy for colorectal cancer screening at the Department of Gastroenterology at Peking Union Medical College Hospital. Under diagnostic colonoscopy procedures, two colonic biopsies were taken from sites showing active mucosal inflammation in the sigmoid colon in patients with UC. Comparable noninflamed sites of colonic mucosa in individuals who were not subsequently diagnosed with inflammatory injury in their colons were used as controls. Immediately after biopsy, a portion of samples was processed for routine histology and pathologic assessment, and the rest was immersed in RNAlater solution (Thermo Fisher Scientific) and stored at -80° for RNA extraction and quantitative reverse transcription (RT)-PCR.

### Cell Cultures

Conditionally immortalized young adult mouse colonocyte (YAMC) and HT-29 cell lines were used. YAMC cells

(passage 7–15) were used according to the protocol described by Whitehead *et al.* (17). Briefly, the cells were maintained in RPMI 1640 medium (Thermo Fisher Scientific) containing 5% heat-inactivated fetal bovine serum (Thermo Fisher Scientific), 5 U/mL mouse interferon- $\gamma$  (IFN- $\gamma$ ; PeproTech, Rocky Hill, NJ, USA), 100 unit/mL penicillin, 100  $\mu$ g/mL streptomycin (Thermo Fisher Scientific), 5  $\mu$ g/mL insulin, 5  $\mu$ g/mL transferrin and 5 ng/mL selenous acid (#354351; BD Biosciences, San Jose, CA, USA) at 33°C as permissive conditions in a water-saturated atmosphere incubator with 5% CO<sub>2</sub> (18). Before experiments, the medium was replaced with one without IFN- $\gamma$  and the cells were moved to 37°C (a nonpermissive temperature) for 24 h to allow them to differentiate. Then, cells were continuously cultured under nonpermissive conditions (IFN- $\gamma$ -free and 37°C) for the duration of the experiment. HT-29 cells (a human intestinal epithelial cell line derived from colonic adenocarcinoma) were purchased from American Type Culture Collection (ATCC, Rockville, MD, USA) and cultured in a water-saturated atmosphere with 5% CO<sub>2</sub> at 37°C. HT-29 cells (passages 20–35 after receipt from ATCC) were maintained in Dulbecco's Modified Eagle Minimum Essential Medium (Thermo Fisher Scientific) containing 100 unit/mL penicillin, 100  $\mu$ g/mL streptomycin and 10% heat-inactivated fetal bovine serum.

### Preparation of Plasmid Constructs

A PCR fragment encoding the full open reading frame of *Sirt6* was generated from mouse mRNA by RT-PCR and processed for DNA sequencing. The sequence data were compared against the National Center for Biotechnology Information database using BLAST. The mouse *Sirt6* coding DNA sequence with no mutations and mismatches was inserted into XhoI and NheI sites of pIRES2-zsGreen1 expression plasmid using a standard molecular cloning protocol of our lab (19). The construct was sequenced to verify

the correct orientation and sequence of the insert and was named pIRES2-zsGreen1-m*Sirt6*.

### Cell Transfections

YAMC cells were seeded onto 6-well plates at densities ranging from 1.5 to  $3 \times 10^5$  cells per well and cultured with complete medium at 33°C overnight. On the second day, the cells were transfected with plasmid DNA (2  $\mu$ g/well) or nucleic acids of siRNAs (50 nM) by using lipofectamine 2000 (Thermo Fisher Scientific) according to the manufacturer's protocol. After 24 h, the medium was replaced with interferon- $\gamma$ -free culture medium. Cells were then cultured at 37°C for an additional 24 h and processed for experiments or harvested for molecular biology studies. siRNAs of *Sirt6*, *Rspo1* or their controls with unrelated sequences were purchased from Origene (Rockville, MD, USA).

### RNA Extraction

Total RNA was isolated from tissues and cultured cells using Trizol solution (Thermo Fisher Scientific), as recommended by the manufacturer. To avoid contamination by DSS, which has been reported to inhibit the activity of both polymerase and reverse transcriptase (20), RNA extracted from colons of DSS-treated mice were further purified using a lithium chloride method previously described by Viennois *et al.* (20). The concentration of RNA was determined by absorbance at 260 nm, and the purity was checked by the 260:280 nm ratio (between 1.8 and 2.0) using an ultraviolet spectrophotometer.

### Quantitative Real-Time RT-PCR

Single-stranded cDNA (20  $\mu$ L) was generated from total RNA samples using iScript cDNA synthesis kit (Bio-Rad, Hercules, CA, USA) according to the protocol provided by the manufacturer, and diluted to 80  $\mu$ L with ddH<sub>2</sub>O. Quantitative real-time PCR for measuring transcripts of a target gene was performed using a protocol modified from our previously published methods (14). Briefly, 96-well microtiter plates were

used for PCR reactions. Each well contained 7.5  $\mu$ L  $2 \times$  SYBR Green PCR Universal Mastermix (Applied Biosystems, Foster City, CA, USA), 0.5  $\mu$ L of 10  $\mu$ M forward primer, 0.5  $\mu$ L of 10  $\mu$ M reverse primer, 2.5  $\mu$ L of ddH<sub>2</sub>O and 4  $\mu$ L of diluted single-stranded cDNA. PCR reactions were conducted in duplicate for each sample using the Fast 7500 real-time PCR system (Applied Biosystems) under the following conditions: 50°C for 5 min, 95°C for 10 min, and then 40 cycles of amplification (95°C for 15 sec and 60°C for 1 min). The cycle at which each sample crossed a fluorescence threshold, CT (at 0.1–0.2 fluorescence units), was determined. The duplicate values for each cDNA were averaged. Fold changes in expression levels of mRNA of a target gene in samples were calculated by using the  $2^{-\Delta\Delta CT}$  method by using GAPDH transcripts as the internal reference (21). The  $\Delta\Delta CT$  value is defined as the CT difference between the normalized amount of sample and the normalized amount of calibrator. Sequences of forward (F) and reverse (R) primers for real-time PCR are listed in Table 1.

### Protein Extraction and Western Blot

Total proteins were isolated from tissues and cells using our previously described protocol (22). The protein concentrations were measured using a Pierce BCA protein assay kit (Thermo Fisher Scientific), following the protocol provided by the manufacturer. Then, proteins (10  $\mu$ g/sample) were mixed with  $2 \times$  Laemmli sample buffer (Bio-Rad) and boiled for 5 min for denaturing. The denatured total proteins were resolved on 4–20% TGX precast sodium dodecyl sulfate polyacrylamide gel electrophoresis gels (Bio-Rad) and transferred onto polyvinylidene difluoride membranes (Bio-Rad) as previously described (22). The membranes containing sample proteins were used for immunodetection of Sirt6 or Rspo1 proteins. Briefly, blots preincubated with PBS containing 5% nonfat dry milk (Bio-Rad) were incubated with primary Ab against Sirt6 (1:1000, CST) or Rspo1 (1:200, LsBio, Seattle, WA, USA) with gentle shaking at 4°C overnight. After incubation, blots were washed three times with PBS containing 0.1%

Tween 20, and then incubated with 5% nonfat dry milk containing 1/6000 diluted horseradish peroxidase-conjugated goat anti-rabbit antibody (Jackson ImmunoResearch, West Grove, PA, USA) for 2 h at room temperature. After additional washing with PBS containing 0.1% Tween 20, immune complexes on the blot were developed with an ECL kit (Thermo Fisher Scientific) and visualized by Bio-Rad ChemiDoc MP System (Bio-Rad). Images were analyzed with Imaging Lab 4.1 software (Bio-Rad). For detection of housekeeping gene expression, blots were stripped and reprobed with a horseradish peroxidase-conjugated mouse mAb against  $\beta$ -actin (1:50,000, clone AC-15, Sigma-Aldrich, St. Louis, MO, USA) followed by development with the ECL kit, scanning and analyzing as described above.

### Induction of Cell Death and Assessment of Cell Viability

It has been shown that development of IBD is associated with numerous types of intestinal epithelial cell death, such as apoptosis, necroptosis and DNA damage related to cell injury (23,24). Thus, we executed models of cell death induced by various cell death inducers: methyl methanesulfonate (MMS, a DNA-damaging reagent), H<sub>2</sub>O<sub>2</sub> (oxidative damage), TNF- $\alpha$  plus cycloheximide (apoptotic challenge) and TNF- $\alpha$  plus z-VAD-fmk (necroptosis stimulation) using YAMC cells. Briefly, cells were subjected to transfection with *siSirt6*/siControl, *pSirt6*/pVector or *siRspo1*/siControl using the protocol described above. After 24 h, the transfected cells were reseeded in 96-well, white-walled, clear-bottomed plates at  $1.5 \times 10^4$  density per well and cultured with IFN- $\gamma$ -free medium at 37°C for 24 h, followed by treatment with adequate cell-death-inducer cocktails: MMS (2 mM), H<sub>2</sub>O<sub>2</sub> (400  $\mu$ M), TNF- $\alpha$  (20 ng/mL) + cycloheximide (5  $\mu$ g/mL) and TNF- $\alpha$  (20 ng/mL) + z-VAD-fmk (20  $\mu$ M). All cell-death-inducer cocktails were prepared in IFN- $\gamma$ -free medium. For MMS treatment, cells were challenged with MMS for 1 h, followed by

**Table 1.** Sequence of qRT-PCR primers

mouse <i>Sirt6</i> -F	5'-AGGCCGCTCTGGTCATTGTC-3'
mouse <i>Sirt6</i> -R	5'-GCACATCACCTCATCCACGTA-3'
mouse <i>Rspo1</i> -F	5'-CGACATGAACAAATGCATCA-3'
mouse <i>Rspo1</i> -R	5'-CTCCTGACACTTGGTGCAGA-3'
mouse <i>Gapdh</i> -F	5'-AACTTTGGCATTGTGGAAGG-3'
mouse <i>Gapdh</i> -R	5'-ACACATTGGGGGTAGGAACA-3'
human <i>SIRT6</i> -F	5'-CCCGGATCAACGGCTCTATC-3'
human <i>SIRT6</i> -R	5'-GCCTTCACCCITTTGGGGG-3'
human <i>GAPDH</i> -F	5'-TGCACCACCAACTGCTTAGC-3'
human <i>GAPDH</i> -R	5'-GGCATGGACTGTGGTCATGAG-3'
mouse <i>Tnf-<math>\alpha</math></i> -F	5'-CCACCACGCTCTCTGTCTA-3'
mouse <i>Tnf-<math>\alpha</math></i> -R	5'-AGGGTCTGGCCATAGAACT-3'
mouse <i>Ifn-<math>\gamma</math></i> -F	5'-TCAAGTGGCATAGATGTGGAAGAA-3'
mouse <i>Ifn-<math>\gamma</math></i> -R	5'-TGGCTCTGCAGGATTTTCATG-3'
mouse <i>Il6</i> -F	5'-ACCAGAGGAAAATTTCAATAGGC-3'
mouse <i>Il6</i> -R	5'-TGATGCACTTGCAGAAAACA-3'
mouse <i>Il10</i> -F	5'-TGAATCCCTGGGTGAGAAG-3'
mouse <i>Il10</i> -R	5'-TGGCCTGTAGACACCTTGG-3'
mouse <i>Mcp-1</i> -F	5'-AGGTCCCTGTGCTGCTCTG-3'
mouse <i>Mcp-1</i> -R	5'-TCTGGACCCATTCCTCTTG-3'
mouse <i>Mip-2<math>\alpha</math></i> -F	5'-GGGAGAGGGTGAGTTGGG-3'
mouse <i>Mip-2<math>\alpha</math></i> -R	5'-GCACACTCCTTCCATGAAAGC-3'
mouse <i>Kc</i> -F	5'-AAAAGGTGTCCTCCAAAGTA-3'
mouse <i>Kc</i> -R	5'-AAGCAGAACTGAACTCCATCG-3'

culture with MMS-free medium for an additional 24 h. For other treatment regimens, cells were treated with adequate cell-death-inducer cocktails for 24 h. At the end of treatments, cell viability was assessed using CellTiter-Glo Assay Kit (Promega, Madison, WI, USA), following the manufacturer's protocol.

### RNA Sequencing

Total RNA was extracted from YAMC cells using RNeasy Micro Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. RNA integrity and quantity were assessed using Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). PolyA-enriched RNA was purified from total RNA using paramagnetic oligo-dT beads, fragmented and used for constructing cDNA libraries with NEBNext Ultra RNA Library Prep Kit for Illumina following the manufacturer's protocol (NEB, Ipswich, MA, USA). Libraries were amplified, followed by removing primers prior to sequencing. These libraries were sequenced on Illumina HiSeq 2500 generating 100 bp paired end reads (Peking Jabrehoo Med Tech Co., Beijing, China). After sequencing, raw reads were cleaned by removing adaptor sequences, empty reads and low-quality sequences. The reads that passed filtering were aligned to reference sequences of the mouse transcriptome (Ensembl release 75) using the Bowtie version 1.0.1 alignment tool. Read counts were normalized using edgeR, and reads per kilobase per million mapped reads values were calculated as the number of counted reads per 1000 mapped and counted bases per geometric mean of normalized read counts per million. Fold change ratio between the two groups was calculated by reads per kilobase per million mapped reads, and an absolute value of  $\log_2$  ratio  $\geq 0.415$  was used as a threshold to judge the difference of gene expression. Heatmaps of differentially expressed genes were generated by the GENE-E visualization and analysis platform. Gene ontology term analysis was performed using Gene Set Enrichment

Analysis software (25,26) and visualized by the REVIGO tool (27).

### Measurement of Myeloperoxidase Activity

Briefly, colon tissues were homogenized in 250  $\mu$ L myeloperoxidase (MPO) assay buffer and centrifuged at 13000g for 10 min at 4°C to remove insoluble material. The supernatants were processed for measurement of MPO activity using an MPO Colorimetric Activity Assay Kit (Sigma-Aldrich), following the manufacturer's protocol. MPO activity was normalized by the protein loading in each sample and reported as unit/gm protein.

### Cytokine and Chemokine Measurements

Plasma cytokine/chemokine measurements were made using Meso Scale Diagnostics (MSD, Gaithersburg, MD, USA) multiplex array technology. Briefly, cytokines and chemokines were measured using a mouse-specific 96-well multispot plate of V-PLEX Plus Proinflammatory Panel 1 Kit (MSD), which included five markers: IL-1 $\beta$ , IL-6, IL-10, TNF- $\alpha$  and KC. The assay was performed according to the manufacturer's instructions. A total volume of 50  $\mu$ L diluted (1:2.5) sample was used in each well. The assay was run in duplicate for each sample. Plate readings were performed on a SECTOR Imager 2400 instrument (MSD). Raw data were analyzed using MSD Discovery Workbench software (version 4.0). The curves were fitted using a 4PL fit with  $1/y^2$  weighting according to the manufacturer's instructions, and concentrations were determined from the standard curves.

### Statistical Analysis

All experiments were performed at least twice. Statistical analysis was performed with Graphpad Prism 6 software. Reported data are the mean  $\pm$  standard error of the mean, and statistical significance was assessed with either the Student *t* test or one-way analysis of variance followed by Fisher's

least significant difference post hoc test.  $P < 0.05$  was considered significant.

### Web Deposition of Data

Data in this study have been deposited in the Gene Expression Omnibus site ([www.ncbi.nlm.nih.gov/geo](http://www.ncbi.nlm.nih.gov/geo)), accession number GSE89620.


## RESULTS

### Sirt6 Is Highly Expressed in Mouse Intestines and Predominantly Localized to Intestinal Epithelial Cells in the Crypt Compartment


We first thought to compare expression patterns of Sirt6 protein in mouse tissues. Using Western blot, we found that Sirt6 protein was widely expressed in different tissues, with particularly strong expressions in the thymus, spleen and intestines (Figure 1A). To further characterize Sirt6 expression in intestines, we examined its cellular localization in the mouse intestines using immunofluorescent staining. While it was strongly detected in crypt epithelial cells (Figure 1B), Sirt6 was weakly presented in other intestinal epithelial cells, suggesting its role in the regulation of intestinal epithelial cell homeostasis.

### Colitis Is Associated with Downregulation of Colonic Sirt6 Expression in Mice and Humans

To examine whether acute colitis affected Sirt6 expression in mouse colons, adult mice (male, 8–10 wks old) were given 3.5% DSS in drinking water *ad libitum* for a period of 7 d to achieve acute experimental colitis using our standard protocol (14). As expected, DSS administration induced experimental colitis in the mice (Supplementary Figure S1). Development of DSS-induced colitis was associated with downregulation of Sirt6 protein (Figure 2A) in a time-dependent manner in mice. Notably, Western blot revealed that some low-molecular-weight bands were presented in colonic tissue samples derived from DSS-treated mice, suggesting that DSS-induced colitis may result in degradation



**Figure 1.** Characterization of Sirt6 protein expression in mouse tissues. (A) Western blot analysis of Sirt6 protein expression in various mouse tissues. Total proteins isolated from indicated mouse tissues (10  $\mu$ g/lane) were subjected to electrophoresis and Western blot using rabbit antibody against mouse Sirt6, as described in Methods. Upper panel: autoradiograph of a representative immunoblot and total protein gel. Lower panel: densitometric analysis of the immunoblot data (normalized to total protein,  $n = 3$ ). Results are expressed as mean  $\pm$  standard error of the mean (SEM). (B) Cellular localization of Sirt6 in mouse intestines. Deparaffinized sections of the small and large intestines of normal mice were stained with immunofluorescence using rabbit antibody against murine Sirt6 or rabbit naïve IgG, as indicated. Nuclei were counterstained with DAPI. Sections were observed by immunofluorescence microscopy. SI, small intestine.



**Figure 2.** Colitis is associated with downregulation of colonic Sirt6 expression in mice and humans. For (A) the mouse colitis model, wild-type C57BL/6J mice (male, 8–10 wks old) were given drinking water containing 3.5% DSS for up to 7 d. Colonic tissues were collected at the indicated time points ( $n = 5$  per time point). For (B) human samples, mucosal biopsies from the sigmoid colons of healthy individuals ( $n = 17$ ) and UC patients ( $n = 15$ ) were obtained through diagnostic colonoscopy procedures. Tissue samples were processed for assessment of expression of Sirt6 protein with (A) Western blot or (B) mRNA, as described in Materials and Methods. (A) Sirt6 protein levels in colon during development of DSS-induced colitis in mice. Upper panel: autoradiograph of a representative immunoblot. Lower panel: densitometric analysis of the immunoblot data (normalized to  $\beta$ -actin). (B) Relative expression of *SIRT6* mRNA in the sigmoid colon biopsies of healthy individuals and UC patients. Results are expressed as mean  $\pm$  SEM. \*,  $P < 0.05$  versus 0 d.

of intestinal Sirt6 protein. Furthermore, we examined intestinal *SIRT6* expression in patients with UC and healthy individuals. UC patients ( $41.4 \pm 13.6$  years old, 7 male and 8 female) with Mayo Endoscopic Score between 1 and 3 were recruited for this study. Among the healthy individuals, 7 were male and 10 were female,  $47.6 \pm 12.0$  years old. Interestingly, we found that the mean value of *SIRT6* mRNA in inflamed mucosa of UC patients was significantly lower than that in colon tissues of healthy individuals (Figure 2B), suggesting a decrease in colonic *SIRT6* gene expression at the transcriptional level in UC patients.

### IFN- $\gamma$ Attenuates Sirt6 Protein Expression in Colonic Epithelial Cells

In this experiment, we examined whether inflammatory mediators modulated Sirt6 expression in colonic epithelial cells. Evidence shows that IFN- $\gamma$  is a dominant proinflammatory cytokine in colitis (28,29). Thus, we first studied the effect of IFN- $\gamma$  treatment on Sirt6 expression in YAMC cells, an epithelial cell line derived

from mouse colonic epithelial cells. We found that Sirt6 protein expression in YAMC cells was markedly inhibited by IFN- $\gamma$  treatment (Figure 3A). As free-radical species are generated during inflammation and affect epithelial cell survival, we determined the effect of hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>, oxidative free radicals) challenge on Sirt6 expression in YAMC cells. Similar to IFN- $\gamma$ , treatment with H<sub>2</sub>O<sub>2</sub> downregulated Sirt6 protein expression in YAMC cells in a dose-dependent manner (Figure 3B). Furthermore, we confirmed that IFN- $\gamma$  inhibited SIRT6 expression in human intestinal epithelial-specific cells (IECs) using HT-29, a human colonic epithelial cell line (Figure 3C).

### Sirt6 Plays a Role in Maintaining the Resistance of Intestinal Epithelial Cells to Cell Death Challenges

Previous studies showed that Sirt6 is a master epigenetic gatekeeper of glucose metabolism, a fundamental cellular event generating metabolic intermediates important for cell growth (30). However, little is known about the role of Sirt6 on intestinal epithelial cell homeostasis. Thus, using both loss-of-function and gain-of-function approaches, we investigated whether Sirt6 regulates intestinal epithelial cell resistance to cell death.

We found that when Sirt6 expression was silenced by transfection with si-Sirt6, a siRNA against Sirt6 transcripts (Figure 4A), YAMC cells had increased cell death in response to various inducers, including MMS (a DNA-damaging reagent), H<sub>2</sub>O<sub>2</sub> (oxidative damage), TNF- $\alpha$  plus cycloheximide (apoptotic challenge) and TNF- $\alpha$  plus z-VAD-fmk (necroptosis stimulation) (Figure 4B).


In addition, when Sirt6 was overexpressed by transfection with pIRES2-zsGreen1-mSirt6, an expression plasmid construct containing the full open reading frame of mouse Sirt6 cDNA (Figure 4C), YAMC cells were markedly resistant to cell death induced by DNA damage, superoxides, apoptotic stimulation and necroptosis signals (Figure 4D). Taken together, our data suggest that Sirt6 renders intestinal epithelial cells resistant to cell death insults.

### Intestinal Epithelial Cell-specific Knockout of Sirt6 Increases Susceptibility to DSS-induced Colitis in Mice


In this study, we first investigated the physiological impact of downregulation of Sirt6 expression in the intestinal epithelium of mice using a tissue-specific knockout approach. Sirt6<sup>Co/Co</sup> mice

(a mouse line harboring a loxP-flanked Sirt6 allele [13]) were crossed with Vil-Cre mice to establish the Sirt6<sup>Co/Co</sup>; Vil-Cre<sup>+/-</sup> (ie, Sirt6<sup>IEC-KO</sup>) mouse line. Genotyping analysis of tail biopsy samples revealed that Sirt6<sup>IEC-KO</sup> mice were characterized as heterozygous for Vil-Cre transgene and homozygous for floxed Sirt6 allele (Supplementary Figure S2A). Using Western blot, we found that Sirt6<sup>IEC-KO</sup> mice lacked Sirt6 protein expression in an intestinal tissue-specific manner (Supplementary Figure S2B). The Sirt6<sup>IEC-KO</sup> mice were fertile and healthy. Their body weights were indistinguishable from those of their control littermates (Supplementary Figure S2C). Histological examination showed that Sirt6<sup>IEC-KO</sup> mice did not display any phenotypical abnormalities in their intestines (Supplementary Figure S2D). Together, the data suggest that Sirt6 expression is not essential for orchestrating morphogenesis and maintaining integrity in intestinal epithelial cells under a normal physiological state.

Next, we examined whether lack of Sirt6 in the intestinal epithelium affected colitis development. For this purpose, Sirt6<sup>IEC-KO</sup> mice and their control littermates were given 3.5% DSS in drinking water *ad libitum* for 7 d to induce colitis. We found that DSS treatment resulted in greater weight loss (Figure 5A) and more severe colitis (Figure 5B) in Sirt6<sup>IEC-KO</sup> mice than that in their control littermates (n = 14–17 mice per group, P < 0.05), specifically in the early period of colitis development. Histological examination showed that Sirt6<sup>IEC-KO</sup> mice displayed more profound signs of colitis at d 7 than their control littermates (Figure 5C). Microscopic scores for DSS-induced colonic inflammation (Figure 5D) and crypt-epithelial injury (Figure 5E) were significantly greater in Sirt6<sup>IEC-KO</sup> mice than that in their control littermates. Furthermore, we found that there was significantly higher MPO activity in the colons of Sirt6<sup>IEC-KO</sup> mice with DSS-induced colitis compared with their control littermates (Figure 5F). Together, our data suggest that the loss of Sirt6 in intestinal



**Figure 3.** Inflammatory mediators attenuate Sirt6 protein expression in mouse and human colonic epithelial cells. (A, B) YAMC and (C) HT-29 cells were subjected to treatments as indicated. After 24 and 48 h, respectively, total cellular proteins were extracted from harvested cells. Levels of Sirt6 protein were accessed with Western blot using anti-Sirt6 antibody, as described in Materials and Methods. Upper panels illustrate the autoradiographs of representative immunoblots; lower panels show densitometric analysis of the immunoblot data (normalized to  $\beta$ -actin). The experiments were performed three times. Results are expressed as mean  $\pm$  SEM. n = 3 in each group. \*, P < 0.05 versus control; \*\*, P < 0.01 versus control; \*\*\*\*, P < 0.0001 versus control.



**Figure 4.** Downregulation of *Sirt6* results in increased susceptibility of mouse colonic epithelial cells to cell death challenges, whereas *Sirt6* overexpression increases resistance of mouse colonic epithelial cells to cell death challenges. (A) Silencing of *Sirt6* expression in colonic epithelial cells was achieved using siRNA technology. The *Sirt6* knockdown *in vitro* was confirmed using qRT-PCR (upper panel) and Western blot (lower panel). (B) Silencing of *Sirt6* increases susceptibility of colonic epithelial cells to cell death challenges. YAMC cells were subjected to transfection with si*Sirt6* or siControl, as described above. Forty-eight hours later, cells were treated with indicated treatments. Twenty-four hours after being challenged with cell death inducers, cell viability was assessed using CellTiter-Glo assay. The experiments were performed three times. Results are expressed as mean  $\pm$  SEM.  $n = 3$  in each group. \*,  $P < 0.05$  versus control; \*\*,  $P < 0.01$  versus control. (C) Ectopic expression of *Sirt6* in intestinal epithelial cells by transfection with p*Sirt6* (ie, pIRES2-zsGreen1-m*Sirt6* plasmid). *Sirt6* overexpression was confirmed with Western blot. pVector, the pIRES2-zsGreen1 plasmid (ie, control). (D) Overexpression of *Sirt6* renders colonic epithelial cells resistant to cell death challenges. YAMC cells were subjected to transfection with p*Sirt6* or pVector, as described in panel C. Forty-eight hours later, they were subjected to indicated treatments. Twenty-four hours later, cell viability was assessed using CellTiter-Glo assay. Results are expressed as mean  $\pm$  SEM and represent average of findings from three independent experiments.  $n = 3$  in each group. \*,  $P < 0.05$  versus control; \*\*,  $P < 0.01$  versus control.

epithelial cells markedly exacerbates DSS-induced colitis.

### ***Sirt6* Plays an Important Role in Sustaining R-spondin-1 Expression in Intestinal Epithelial Cells under Inflammation**


It has been reported that *Sirt6* modulates cellular homeostasis via shaping of diverse transcriptional networks (31,32). To determine whether *Sirt6* is capable of influencing gene expression in intestinal epithelial cells under physiological and inflammatory conditions, we knocked down *Sirt6* using siRNA-mediated gene silencing in YAMC cells. Then, we performed RNA-seq transcriptome analysis

in naïve and TNF- $\alpha$ -treated *Sirt6*-silenced YAMC cells to enrich for direct *Sirt6* targets associated with inflammatory stimulation. By comparing *Sirt6*-silenced YAMC cells to siControl-transfected YAMC cells, we found that there were 916 (Supplementary Tables S1 and S3) and 1026 (Supplementary Tables S2 and S3) differentially expressed genes in the naïve and TNF- $\alpha$  treatment conditions, respectively (Figure 6A). We also found that there were 302 genes that were co-expressed differentially in both naïve and TNF- $\alpha$  treatment conditions between *Sirt6*-silenced and siControl-transfected YAMC cells (Figure 6A and Supplementary Table S3).

Among the differentially expressed genes, we found numerous targets related to cell proliferation in cells treated with TNF- $\alpha$  (Figure 6B). The hierarchical clustering revealed that *Sirt6* silencing markedly affected global gene transcription in intestinal epithelial cells under naïve and TNF- $\alpha$  treatment conditions (Figure 6C). Notably, the differential gene expression analysis indicates downregulation of *R-spondin-1* (*Rspo1*) in TNF- $\alpha$ -treated *Sirt6*-knockdown YAMC cells (Figure 6C).

*Rspo1* is a Wnt signaling pathway-associated mitogen (33,34). Previously, Zhao *et al.* showed that *Rspo1* ameliorates DSS-induced colitis in mice (35). Thus, we further verified the effect of





**Figure 5.** Intestinal epithelial cell-specific knockout of *Sirt6* gene increases susceptibility to DSS-induced colitis in mice. *Sirt6*<sup>IEC-KO</sup> mice (n = 14) and their control littermates (n = 17) (male, 8–10 wks old) were given drinking water containing 3.5% DSS for 7 d. A set of mice received normal drinking water as controls. (A) Body weight and (B) disease activity index (DAI) were monitored on a daily basis. Mice were euthanized at d 7 of DSS treatment. (C) Colonic tissues were processed for routine histology and H&E staining and assessed in a double-blind fashion for histological colonic tissue injury in terms of (D) inflammation severity and (E) crypt of damage using a scoring system described in Materials and Methods. (F) The severity of colitis was further determined by MPO assay. Results are expressed as mean  $\pm$  SEM. \*,  $P < 0.05$  versus control.

TNF- $\alpha$  on *Rspo1* expression in YAMC cells using qRT-PCR and Western blot. We confirmed that reduction of *Rspo1* mRNA and protein levels occurred in *Sirt6*-silenced IECs after TNF- $\alpha$  treatment *in vitro* (Figures 7A and 7B). In addition, knocking out *Sirt6* in intestinal epithelial cells *in vivo* did not affect intestinal *Rspo1* expression at baseline (Figure 7C). In contrast, treatment of *Sirt6*<sup>IEC-KO</sup> mice


with lipopolysaccharide resulted in downregulation of *Rspo1* mRNA (Supplementary Figure 3) and protein expression in colons (Figure 7C). Similarly, we found a trend of decreasing *Rspo1* protein levels in colons of wild-type littermate mice with DSS-induced colitis (Figure 7D). Furthermore, a significant reduction of *Rspo1* protein expression was observed in *Sirt6*<sup>IEC-KO</sup> mice

compared with control littermates under a colitis condition (Figure 7D). Finally, we performed an *in vitro* study to examine whether *Rspo1* mediates the protective role of *Sirt6* that was revealed in the experiments described in Figure 4. We found that silencing *Rspo1* with siRNA technology resulted in diminishing the beneficial effect of *Sirt6* overexpression on protection of YAMC cells against cell death induced by MMS, H<sub>2</sub>O<sub>2</sub>, TNF- $\alpha$  plus cycloheximide and TNF- $\alpha$  plus z-VAD-fmk (Figure 8). Collectively, our data suggest that *Sirt6* has an important role in protecting intestinal epithelial cells under inflammation by maintaining expression of the *Rspo1* gene.

## DISCUSSION

In the present study, we investigated the role of intestinal epithelial *Sirt6* in gut injury and inflammation. Our findings show that *Sirt6* is expressed by intestinal epithelial cells, predominantly in crypt cells. We demonstrated that colitis is associated with decreased levels of intestinal *Sirt6*. Inflammatory mediators, including IFN- $\gamma$  and reactive oxygen species, directly inhibited *Sirt6* expression in intestinal epithelial cells. Mice deficient in *Sirt6* in intestinal epithelial cells are prone to DSS-induced colonic mucosal injury, suggesting that inflammation-induced impairment of *Sirt6* expression in intestines contributes to the pathogenesis of colitis. Furthermore, we found for the first time that *Sirt6* is critical in maintaining levels of *Rspo1* in intestinal epithelial cells under inflammatory conditions. Since *Rspo1* is an important trophic factor for intestinal epithelial cell growth (35,36), our data strongly suggest the notion that *Sirt6* plays a central role in protecting against colitis-associated intestinal epithelial cell injury via preservation of *Rspo1*.

Emerging studies have shown that *Sirt6* is a key regulator of genome stability, glucose homeostasis, metabolism and inflammation (9). It governs diverse cellular functions, such as transcription, telomere integrity and DNA repair (9). Mouse pups with whole-body *Sirt6*




**Figure 6.** Abolishing Sirt6 expression impacts transcriptome responses to TNF- $\alpha$  stimulation in colonic epithelial cells. YAMC cells were transfected with *Sirt6* siRNA as described in Materials and Methods. Forty-eight hours after transfection, cells were cultured with medium containing TNF- $\alpha$  (100 ng/mL) or medium alone for an additional 24 h. At the end of treatment, cells were harvested for RNA extraction, followed by RNA-seq transcriptome analysis. (A) Differential gene expression analysis ( $\log_2$  ratio  $\geq 0.415$  fold change) was carried out to determine genes that were altered in YAMC cells transfected with siSirt6 compared with scramble siRNA (siControl) under either naïve condition (purple circle) or TNF- $\alpha$  stimulation (orange circle). Venn diagram demonstrates the number of shared or specific genes of each group of cells. (B) Analysis of Gene Ontology (GO) terms to identify enriched GO terms associated with *Sirt6* silencing. The genes from each category in the Venn diagram were subjected to GO analysis to identify GO terms enrichment using GESA software. Results are illustrated as a scatterplot using the REViGO visualization tool. The circle size is proportional to the frequency of the GO term, while the color represents the normalized enrichment score generated from GESA (red: higher; blue: lower). (C) The genes from each category in the Venn diagram were further subjected to hierarchical cluster analysis of common differentially expressed genes associated with *Sirt6* silencing in naïve and TNF- $\alpha$  stimulation conditions.

deficiency exhibit postnatal growth retardation and eventually die at about 4 wks after birth, highlighting the importance of Sirt6 for growth and survival (11).

Furthermore, a distinctive phenotype of colitis with prominent epithelial sloughing was previously found in weaning *Sirt6*-null mice (11), suggesting that Sirt6


is required in remodeling tissue architecture as intestinal mucosa grow and mature during postnatal development. However, we did not find a significant



**Figure 7.** Sirt6 is required to maintain Rspo1 expression of intestinal epithelial cells under inflammation status. (A and B) YAMC cells ( $n=3$  in each group) were transfected with *Sirt6* siRNA (siSirt6, 50 nM) or negative control siRNA (siControl, 50 nM) using lipofectamine 2000. Forty-eight hours after transfection, cells were cultured with medium containing TNF- $\alpha$  (100 ng/mL) or medium alone for an additional 24 h. At the end of treatment, cells were harvested to measure expression of (A) *Rspo1* mRNA with quantitative real-time RT-PCR and (B) Rspo1 protein with Western blot. (C) *Sirt6*<sup>IEC-KO</sup> mice and their control littermates (male, 8–10 wks old,  $n=4$  in each group) were intraperitoneally injected with either LPS (2 mg/kg) or saline (100  $\mu$ L, sham control). Twenty-four hours after treatment, mice were euthanized by CO<sub>2</sub> inhalation. Then, colons were collected and processed to determine levels of Rspo1 protein by Western blot. (D) Western blot examination of Rspo1 protein expression in *Sirt6*<sup>IEC-KO</sup> mice and their control littermates (male, 8–10 wks old,  $n=4$  in each group) with DSS-induced colitis. Colonic tissues were collected on d 7 after induction of colitis with 3.5% DSS drinking water. Results are expressed as mean  $\pm$  SEM and represent the average of findings from three independent experiments. \*,  $P < 0.05$  versus control; \*\*,  $P < 0.01$  versus control; \*\*\*,  $P < 0.001$  versus control.

effect of intestinal epithelial deletion of *Sirt6* on intestinal morphology in mice, implying that *Sirt6* in intestinal epithelial cells is not an essential protein for intestinal development and homeostasis in normal physiological states.

Evidence suggests that *Sirt6* expression is inhibited in numerous pathological conditions associated with inflammation. For example, decreased *Sirt6* expression in fetal membranes occurs in preterm labor (37). Balestrieri *et al.* found that



**Figure 8.** Rspo1 is required for protection of intestinal epithelial cells against cell death challenges by Sirt6 overexpression. YAMC cells were subjected to treatment as indicated using a protocol described in Figure 4. At the end of treatment, cells were processed to measure cell viability using CellTiter-Glo assay. Results are expressed as mean  $\pm$  SEM.  $n = 4$  in each group. \*,  $P < 0.05$  versus pVector + siControl; #,  $P < 0.05$  versus pSirt6 + siControl.

*Sirt6* protein expression is downregulated in diabetic atherosclerotic lesions (38). A previous study identified that H<sub>2</sub>O<sub>2</sub> treatment results in marked reduction of *Sirt6* in endothelial cells (39). Consistent with these previous findings, our data indicate that mucosal *Sirt6* protein expression is decreased in colitis. Furthermore, we found that not only H<sub>2</sub>O<sub>2</sub>, but also IFN- $\gamma$  is a strong inhibitor of *Sirt6* expression in intestinal epithelial cells. In addition, our study shows that deletion of *Sirt6* in intestinal epithelial cells exacerbates DSS-induced colitis, strongly supporting the notion that inflammation-induced downregulation of intestinal epithelial *Sirt6* directly impacts intestinal mucosal integrity during colitis development.

*Sirt6* is an enzyme that has ADP-ribosyltransferase activity (40,41) and histone deacetylase activity (42–45). It influences chromatin structure and gene expression. Particularly, previous studies demonstrated that *Sirt6* functions at chromatin to attenuate NF- $\kappa$ B-dependent transcription (46). On the other hand, *Sirt6* was found to positively regulate TNF- $\alpha$  production at the post-transcriptional level *in vitro* (47). Thus, the effect

of downregulation of Sirt6 in regulating the inflammatory response may be complicated *in vivo*. Indeed, our data show that knockout of *Sirt6* in intestinal epithelial cells did not influence the cytokine profile in colitis (Supplementary Figure S4), while the *Sirt6*<sup>IEC-KO</sup> mice were more susceptible to DSS-induced colitis than their control littermates. This observation suggests that Sirt6 protects intestinal epithelial cells against inflammatory injury through a cytokine-independent mechanism. Using global RNA expression data obtained by RNA-seq transcriptome analysis, we found that knockdown of *Sirt6* markedly alters gene expression in naïve intestinal epithelial cells. Furthermore, we found that the response to TNF- $\alpha$  challenge in *Sirt6*-silenced IECs differs from that in IECs with intact Sirt6 expression. Together, it appears that Sirt6 plays an important role in maintaining the homeostasis of gene expression in intestinal epithelial cells in both the normal physiological state and inflammation.

In addition, our finding that knocking down Sirt6 expression in intestinal epithelial cells decreases Rspo1 expression in inflammation is intriguing. Rspo1 is a trophic factor for intestinal epithelial cells (35,36). Previously, Zhao *et al.* (35) reported that Rspo1 is predominantly expressed in crypt Paneth cells and differentiated enterocytes along the intestinal villus epithelium, where Sirt6 is also expressed in the mouse gut. Wnt/ $\beta$ -catenin signaling plays an essential role in regulating gastrointestinal homeostasis. Rspo1 has been shown to stimulate intestinal epithelial cell proliferation and protect epithelial cells from constant exposure to toxins, inflammatory cytokines and reactive oxygen radicals by increasing  $\beta$ -catenin nuclear localization and subsequently turning on Wnt downstream target gene activation (35,48,49). Administration of recombinant Rspo1 was reported to strongly ameliorate colitis symptoms in several experimental colitis mouse models (35,48,50), suggesting that it has a protective role in the gut under inflammation. We show here that a decrease in Rspo1 expression is

associated with an increase in sensitivity to various death inducers in *Sirt6* knockdown cells. *Sirt6*<sup>IEC-KO</sup> mice exhibit a lack of ability to maintain Rspo1 expression in their intestines under inflammation, implying that an increase in susceptibility to inflammatory intestinal injury in *Sirt6*<sup>IEC-KO</sup> mice may be due to a lack of the protective factor Rspo1. Furthermore, we found that Rspo1 mediates the role of Sirt6 in the protection of intestinal epithelial cells against cell injury. Together, our data in combination with previous findings support the notion that the Sirt6-Rspo1 signal axis plays a role in the protection of intestinal epithelial cells against inflammatory injury.

## CONCLUSION

In summary, our study reveals that expression of Sirt6 in intestinal epithelial cells is necessary for protection of the intestinal mucosa against colitis. We identified that intestinal inflammation causes downregulation of Sirt6 in the gut, which leads to increased susceptibility of intestinal epithelial cells to injury. In addition, we found Rspo1 to be regulated by Sirt6 in intestinal epithelial cells. Our data suggest that inflammation-induced downregulation of Sirt6 contributes to decreased Rspo1 expression in intestinal epithelial cells, thus leading to an increased susceptibility of the intestinal mucosa to injury under inflammatory conditions. These findings provide novel insights into both the pathogenesis of colitis and potential therapeutic targets for intestinal injury and inflammation.

## DISCLOSURE

The authors declare that they have no competing interests as defined by *Molecular Medicine* or other interests that might be perceived to influence the results and discussion reported in this paper.

## ACKNOWLEDGMENTS

This study was supported by National Institute of Diabetes and Digestive and Kidney Diseases grant R01DK064240 (XDT), National Institute of General Medical Sciences grant R01GM117628

(XDT), Eunice Kennedy Shriver National Institute of Child Health and Human Development grant R01HD060876 (IDP), US Department of Veterans Affairs Merit Award I01BX001690 (XDT), the Dorothy M and Edward E Burwell Professorship (XDT) and Ministry of Health of the People's Republic of China Special Project grant 201002020 (JQ). The sponsors had no role in study design or collection, analysis or interpretation of the data.

## REFERENCES

1. Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. (2011) Epidemiology and natural history of inflammatory bowel diseases. *Gastroenterology*. 140:1785–94.
2. Kaplan GG. (2015) The global burden of IBD: from 2015 to 2025. *Nat. Rev. Gastroenterol. Hepatol.* 12:720–27.
3. Molodecky NA, *et al.* (2012) Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. *Gastroenterology*. 142:46–54, e42, quiz e30.
4. Henderson P, van Limbergen JE, Schwarze J, Wilson DC. (2011) Function of the intestinal epithelium and its dysregulation in inflammatory bowel disease. *Inflamm. Bowel Dis.* 17:382–95.
5. Ananthakrishnan AN. (2015) Epidemiology and risk factors for IBD. *Nat. Rev. Gastroenterol. Hepatol.* 12:205–17.
6. North BJ, Verdin E. (2004) Sirtuins: Sir2-related NAD-dependent protein deacetylases. *Genome Biol.* 5:224.
7. Caruso R, *et al.* (2014) Defective expression of SIRT1 contributes to sustain inflammatory pathways in the gut. *Mucosal Immunol.* 7:1467–79.
8. Yang H, *et al.* (2012) SIRT1 activators suppress inflammatory responses through promotion of p65 deacetylation and inhibition of NF-kappaB activity. *PLoS One.* 7:e46364.
9. Kugel S, Mostoslavsky R. (2014) Chromatin and beyond: the multitasking roles for SIRT6. *Trends Biochem. Sci.* 39:72–81.
10. Kanfi Y, Naiman S, Amir G, Peshti V, Zinman G. (2012) The sirtuin SIRT6 regulates lifespan in male mice. *Nature.* 483:218–21.
11. Mostoslavsky R, *et al.* (2006) Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. *Cell.* 124:315–29.
12. el Marjou F, *et al.* (2004) Tissue-specific and inducible Cre-mediated recombination in the gut epithelium. *Genesis.* 39:186–93.
13. Kim HS, *et al.* (2010) Hepatic-specific disruption of SIRT6 in mice results in fatty liver formation due to enhanced glycolysis and triglyceride synthesis. *Cell Metab.* 12:224–36.
14. Chogle A, *et al.* (2011) Milk fat globule-EGF factor 8 is a critical protein for healing of dextran sodium sulfate-induced acute colitis in mice. *Mol. Med.* 17:502–07.

15. Bu HF, et al. (2007) Milk fat globule-EGF factor 8/lactadherin plays a crucial role in maintenance and repair of murine intestinal epithelium. *J. Clin. Invest.* 117:3673–83.
16. Zhu YQ, Tan XD. (2005) TFF3 modulates NF-[kappa]B and a novel negative regulatory molecule of NF-[kappa]B in intestinal epithelial cells via a mechanism distinct from TNF-[alpha]. *Am. J. Physiol. Cell Physiol.* 289:C1085–93.
17. Whitehead RH, VanEeden PE, Noble MD, Ataliotis P, Jat PS. (1993) Establishment of conditionally immortalized epithelial cell lines from both colon and small intestine of adult H-2Kb-tsA58 transgenic mice. *Proc. Natl. Acad. Sci. USA.* 90:587–91.
18. Yan F, et al. (2013) A Lactobacillus rhamnosus GG-derived soluble protein, p40, stimulates ligand release from intestinal epithelial cells to transactivate epidermal growth TNFfactor receptor. *J. Biol. Chem.* 288:30742–51.
19. Wang X, Bu HF, Liu SX, De Plaen IG, Tan XD. (2015) Molecular mechanisms underlying the regulation of the MFG-E8 gene promoter activity in physiological and inflammatory conditions. *J. Cell. Biochem.* 116:1867–79.
20. Viennois E, Chen F, Laroui H, Baker MT, Merlin D. (2013) Dextran sodium sulfate inhibits the activities of both polymerase and reverse transcriptase: lithium chloride purification, a rapid and efficient technique to purify RNA. *BMC Res. Notes.* 6:360.
21. Livak KJ, Schmittgen TD. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods.* 25:402–08.
22. Bu HF, et al. (2006) Lysozyme-modified probiotic components protect rats against polymicrobial sepsis: role of macrophages and cathelicidin-related innate immunity. *J. Immunol.* 177:8767–76.
23. Nunes T, Bernardazzi C, de Souza HS. (2014) Cell death and inflammatory bowel diseases: apoptosis, necrosis, and autophagy in the intestinal epithelium. *Biomed. Res. Int.* 2014:218493.
24. Negroni A, Cucchiara S, Stronati L. (2015) Apoptosis, necrosis, and necroptosis in the gut and intestinal homeostasis. *Mediators Inflamm.* 2015:250762.
25. Subramanian A, et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc. Natl. Acad. Sci. USA.* 102:15545–50.
26. Mootha VK, et al. (2003) PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. *Nat. Genet.* 34:267–73.
27. Supek F, Bosnjak M, Skunca N, Smuc T. (2011) REVIGO summarizes and visualizes long lists of gene ontology terms. *PLoS One.* 6: e21800.
28. Neurath MF. (2014) Cytokines in inflammatory bowel disease. *Nat. Rev. Immunol.* 14:329–42.
29. Ito R, et al. (2006) Interferon-gamma is causatively involved in experimental inflammatory bowel disease in mice. *Clin. Exp. Immunol.* 146:330–38.
30. Zhong L, Mostoslavsky R. (2010) SIRT6: a master epigenetic gatekeeper of glucose metabolism. *Transcription.* 1:17–21.
31. Kawahara TL, et al. (2011) Dynamic chromatin localization of Sirt6 shapes stress- and aging-related transcriptional networks. *PLoS Genet.* 7:e1002153.
32. Lerrer B, Gertler AA, Cohen HY. (2016) The complex role of SIRT6 in carcinogenesis. *Carcinogenesis.* 37:108–18.
33. Kim KA, et al. (2008) R-Spondin family members regulate the Wnt pathway by a common mechanism. *Mol. Biol. Cell.* 19:2588–96.
34. Binnerts ME, et al. (2007) R-Spondin1 regulates Wnt signaling by inhibiting internalization of LRP6. *Proc. Natl. Acad. Sci. USA.* 104:14700–05.
35. Zhao J, et al. (2007) R-spondin1, a novel intestinotrophic mitogen, ameliorates experimental colitis in mice. *Gastroenterology.* 132:1331–43.
36. Kim KA, et al. (2005) Mitogenic influence of human R-spondin1 on the intestinal epithelium. *Science.* 309:1256–59.
37. Lim R, Barker G, Lappas M. (2013) SIRT6 is decreased with preterm labor and regulates key terminal effector pathways of human labor in fetal membranes. *Biol. Reprod.* 88:17.
38. Balestrieri ML, et al. (2015) Sirtuin 6 expression and inflammatory activity in diabetic atherosclerotic plaques: effects of incretin treatment. *Diabetes.* 64:1395–406.
39. Liu R, Liu H, Ha Y, Tilton RC, Zhang W. (2014) Oxidative stress induces endothelial cell senescence via downregulation of Sirt6. *Biomed. Res. Int.* 2014:902842.
40. Liszt G, Ford E, Kurtev M, Guarente L. (2005) Mouse Sir2 homolog SIRT6 is a nuclear ADP-ribosyltransferase. *J. Biol. Chem.* 280:21313–20.
41. Corda D, Di Girolamo M. (2003) Functional aspects of protein mono-ADP-ribosylation. *EMBO J.* 22:1953–58.
42. Yang B, Zwaans BM, Eckersdorff M, Lombard DB. (2009) The sirtuin SIRT6 deacetylates H3 K56Ac in vivo to promote genomic stability. *Cell Cycle.* 8:2662–63.
43. Sebastian C, et al. (2012) The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism. *Cell.* 151:1185–99.
44. Michishita E, et al. (2008) SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin. *Nature.* 452:492–96.
45. Michishita E, et al. (2009) Cell cycle-dependent deacetylation of telomeric histone H3 lysine K56 by human SIRT6. *Cell Cycle.* 8:2664–66.
46. Kawahara TL, et al. (2009) SIRT6 links histone H3 lysine 9 deacetylation to NF-kappaB-dependent gene expression and organismal life span. *Cell.* 136:62–74.
47. Jiang H, et al. (2013) SIRT6 regulates TNF-alpha secretion through hydrolysis of long-chain fatty acyl lysine. *Nature.* 496:110–13.
48. Bhanja P, et al. (2009) Protective role of R-spondin1, an intestinal stem cell growth factor, against radiation-induced gastrointestinal syndrome in mice. *PLoS One.* 4:e8014.
49. Zhao J, Kim KA, Abo A. (2009) Tipping the balance: modulating the Wnt pathway for tissue repair. *Trends Biotechnol.* 27:131–36.
50. Zhao J, et al. (2009) R-Spondin1 protects mice from chemotherapy or radiation-induced oral mucositis through the canonical Wnt/beta-catenin pathway. *Proc. Natl. Acad. Sci. USA.* 106:2331–36.

Cite this article as: Liu F, et al. (2017) Sirtuin-6 preserves R-spondin-1 expression and increases resistance of intestinal epithelium to injury in mice. *Mol. Med.* 23:272–284.